Hypertrophic obstructive cardiomyopathy is the most common inherited cardiac disease (autosomal dominant, ~1 in 500), characterized by asymmetric left ventricular hypertrophy with dynamic left ventricular outflow tract obstruction (LVOTO), and is a leading cause of sudden cardiac death (SCD) in young adults. [1-2] Two-thirds of HCM patients have LVOT obstruction at rest or with provocation. [3]
1. History
- Exertional symptoms: dyspnea, chest pain, fatigue, presyncope/syncope — all typically provoked by exertion, dehydration, or postprandial states [4-5]
- Characterize timing: onset with activity, relieved by rest or recumbency; worsened by standing, Valsalva, or heat
- Palpitations — may indicate atrial fibrillation (present in >50% paroxysmal) or ventricular arrhythmia [4-5]
- Orthopnea and PND if congestive symptoms develop
- Ask about prior cardiac arrest, ICD shocks, or documented arrhythmias
- Important negatives: absence of pleuritic pain, positional pain, fever, cough (helps exclude other causes of dyspnea/chest pain)
2. Alarm Features
- Syncope — especially exertional or without prodrome; recent syncope (within 6 months) is a major SCD risk marker [6]
- Cardiac arrest or sustained ventricular tachycardia [2][6]
- Acute hemodynamic collapse/hypotension — a medical urgency in obstructive HCM; can be precipitated by vasodilators, dehydration, or tachyarrhythmia [6]
- New-onset atrial fibrillation with rapid ventricular response — can cause acute decompensation and carries high stroke risk [1][7]
- Progressive dyspnea at rest or NYHA class III–IV symptoms
- Family history of SCD in a first-degree relative <50 years old [6]
3. Medications
First-line treatments (per 2024 AHA/ACC Guidelines): [6]
- Nonvasodilating beta-blockers (e.g., metoprolol, propranolol, nadolol) — titrate to resting HR 50–60 bpm [2][5]
- Nondihydropyridine calcium channel blockers (verapamil, diltiazem) — substitute if beta-blockers ineffective or not tolerated; avoid combining with beta-blockers for HCM-directed therapy [6][8]
Second-line / add-on: [6]
- Disopyramide — potent negative inotrope; must be combined with an AV nodal blocker to prevent rapid AF conduction [6][8]
- Cardiac myosin inhibitors: mavacamten (Camzyos, FDA-approved 2022) and aficamten (Myqorzo, FDA-approved 2025) — reduce hypercontractility and LVOT gradients [6][9-10]
Contraindicated / to avoid: [6][8]
- Pure vasodilators: dihydropyridine CCBs (amlodipine, nifedipine), nitrates, ACE inhibitors, ARBs
- Positive inotropes: dobutamine, dopamine, digoxin
- High-dose diuretics (reduce preload → worsen obstruction)
- ADHD stimulant medications
- Excessive caffeine and alcohol
4. Diet
- Adequate hydration is critical — dehydration reduces preload and worsens LVOTO [8]
- Avoid large, heavy meals (postprandial splanchnic vasodilation can provoke symptoms)
- Limit excessive caffeine and alcohol intake [8]
- Maintain healthy body weight [8]
- No specific long-term dietary restrictions beyond the above
5. Review of Systems
- Cardiovascular: chest pain, dyspnea, palpitations, syncope/presyncope, orthopnea, edema
- Neurologic: lightheadedness, transient loss of consciousness, focal deficits (embolic stroke from AF)
- Respiratory: exercise intolerance, paroxysmal nocturnal dyspnea
- GI: postprandial worsening of symptoms
- Psychiatric: anxiety, depression (common with chronic disease and activity restriction)
- Screen for sleep-disordered breathing (comorbidity that worsens HCM) [11]
6. Collateral History and Family History
- Three-generation family history is recommended at initial evaluation [4][12]
- Ask specifically about SCD, unexplained drowning, single-vehicle accidents, or unexplained death in relatives <50 years [6]
- Family members with known HCM, ICDs, or heart failure
- Autosomal dominant inheritance — pathogenic sarcomere gene variants found in 30–60% of cases [1][4]
- First-degree relatives require screening with ECG and echocardiography [4]
- Genetic counseling by a counselor versed in cardiac genetics is strongly recommended [4]
7. Risk Factors
- Family history of HCM or HCM-related SCD [6]
- Sarcomere gene mutations (8 genes identified; most common: MYH7, MYBPC3) [4]
- Young age — SCD risk is highest in younger patients and inversely related to age [2][6]
- Massive LV hypertrophy (wall thickness ≥30 mm) [6]
- LV apical aneurysm [6]
- Extensive late gadolinium enhancement (≥15% LV mass) on CMR [6]
- LVEF <50% (end-stage phase) [6]
- Nonsustained ventricular tachycardia on Holter [6]
- Comorbidities: hypertension, obesity, obstructive sleep apnea, atrial fibrillation [11]
8. Differential Diagnosis
- Hypertensive heart disease — can produce LVH but rarely >20 mm wall thickness; requires uncontrolled hypertension [13]
- Athlete's heart — physiologic LVH typically concentric, ≤13 mm, with normal diastolic function; regresses with detraining [14]
- Cardiac amyloidosis — consider if LVH with low voltage on ECG, diastolic dysfunction, apical sparing on strain imaging [11][13]
- Fabry disease — X-linked, concentric LVH, renal/dermatologic features; check alpha-galactosidase A [11][13]
- Aortic stenosis — fixed obstruction; crescendo-decrescendo murmur radiating to carotids; murmur decreases with Valsalva (opposite of HOCM)
- Mitochondrial cardiomyopathy — consider in pediatric patients with multisystem disease [11]
- Glycogen storage diseases (Pompe, Danon) — especially in young patients with massive hypertrophy
9. Past Medical History
- Prior episodes of syncope, cardiac arrest, or documented arrhythmias
- Known ICD or pacemaker
- Prior septal reduction therapy (myectomy or alcohol septal ablation)
- Atrial fibrillation history and anticoagulation status
- Comorbid hypertension, coronary artery disease, valvular disease
- Obstructive sleep apnea
- Pregnancy history (hemodynamic changes can exacerbate LVOTO)
10. Physical Exam
- Harsh crescendo-decrescendo systolic murmur at left lower sternal border/apex [1][5]
- Increases with Valsalva, standing, dehydration (decreased preload/afterload)
- Decreases with squatting, leg elevation, hand grip (increased preload/afterload)
- Separate murmur of mitral regurgitation — holosystolic at apex, radiating to axilla [5]
- Brisk, bifid (bisferiens) carotid pulse
- Prominent apical impulse; may have S4 gallop
- Jugular venous distension and peripheral edema if decompensated
- Vital signs: assess for hypotension (medical urgency), tachycardia, irregular rhythm (AF)
11. Lab Studies
- BNP/NT-proBNP — elevated with heart failure symptoms; useful for monitoring [7]
- Troponin — may be mildly elevated chronically; rule out acute coronary syndrome in chest pain presentations
- BMP — assess renal function (relevant for medication dosing and diuretic use)
- TSH — thyrotoxicosis can exacerbate symptoms
- CBC — rule out anemia as contributor to symptoms
- Genetic testing — sarcomere gene panel after genetic counseling; identifies pathogenic variants in 30–60% [4]
- Alpha-galactosidase A (if Fabry suspected), serum/urine protein electrophoresis (if amyloid suspected) [11][13]
12. Imaging
First-line: Transthoracic echocardiography [6][13]
- Diagnostic criterion: maximal LV end-diastolic wall thickness ≥15 mm (≥13 mm with family history or positive genetic test) [1][4][13]
- Assess LVOT gradient at rest and with provocation (Valsalva, exercise)
- LVOT gradient ≥30 mm Hg defines obstruction; ≥50 mm Hg is the threshold for intervention [13]
- Evaluate mitral valve anatomy, systolic anterior motion (SAM), mitral regurgitation, EF, LA size
Exercise stress echocardiography — preferred method to provoke latent LVOTO when resting gradient is <30 mm Hg [6][12]
Cardiac MRI (CMR): [2][12-13]
- Gold standard for wall thickness measurement and tissue characterization
- Identifies LV apical aneurysm, extent of late gadolinium enhancement (LGE ≥15% LV mass = high SCD risk)
- Differentiates HCM from phenocopies (amyloid, Fabry)
- Repeat every 3–5 years for surveillance [12]
Cardiac CT — alternative when CMR is contraindicated; evaluates coronary anatomy and myocardial bridging [2]
13. Special Tests
- Ambulatory ECG monitoring (24–48 hr Holter or ≥2-week wireless patch) — detect NSVT, AF [6][12-13]
- Cardiopulmonary exercise testing (CPET) — objective assessment of functional capacity; useful when symptom severity is uncertain [8][12]
- Exercise stress echocardiography — provoke latent LVOT gradients [12]
- Genetic testing with pre-test counseling — 8 sarcomere genes associated with HCM [4]
- SCD risk calculators — HCM Risk-SCD (ESC) and AHA/ACC individual risk marker strategy to guide ICD decisions [6][13]
The following algorithm from the AHA/ACC guidelines outlines the ICD decision-making framework:
14. ECG
ECG is abnormal in ~90–95% of HCM patients: [1][4-5][14]
- LV hypertrophy voltage criteria
- Prominent Q waves — especially in inferior and lateral leads (septal depolarization)
- ST-segment depression and T-wave inversions — particularly in lateral/anterolateral leads
- Left axis deviation
- P-wave abnormalities (left atrial enlargement)
- Giant negative T waves in precordial leads — suggest apical variant HCM [5][15]
- A normal ECG does not exclude HCM but is present in only 5–10% of cases [5][13]
Dangerous patterns to recognize:
- Sustained or nonsustained ventricular tachycardia
- Atrial fibrillation with rapid ventricular response
- Pre-excitation (WPW) — associated with some HCM subtypes
15. Assessment
- HOCM is a chronic, progressive genetic cardiomyopathy with dynamic LVOTO that is highly variable throughout daily life [6]
- Severity stratification is based on: NYHA functional class, resting/provoked LVOT gradient, LV wall thickness, EF, presence of SCD risk markers [6][12]
- Most patients achieve normal longevity with appropriate management; annual SCD rate ~1% before ICD era [2]
- Atypical presentations include isolated AF, embolic stroke, or incidental murmur/ECG finding [4-5]
- Complications: SCD, progressive heart failure, atrial fibrillation with stroke, infective endocarditis (rare), end-stage (burned-out) phase with EF <50% [2][7]
16. Treatment Plan
The following figure from Braunwald's 2025 NEJM review illustrates the stepwise treatment algorithm:
Initial stabilization (ED setting): [6]
- Acute hypotension is a medical urgency: IV fluids for volume resuscitation, IV phenylephrine (pure alpha-agonist to increase afterload), IV beta-blocker to reduce contractility and HR
- Avoid vasodilators, inotropes, and aggressive diuresis
- Trendelenburg positioning; passive leg raise
Chronic pharmacologic management (per 2024 AHA/ACC): [6]
- Nonvasodilating beta-blockers — first-line; titrate to resting HR 50–60 bpm
- Verapamil or diltiazem — if beta-blockers fail or are not tolerated
- Escalation if persistent symptoms: add disopyramide (with AV nodal blocker), or cardiac myosin inhibitor (mavacamten or aficamten), or refer for septal reduction therapy (SRT)
Septal reduction therapy (at experienced HCM centers): [6]
- Surgical myectomy — gold standard; preferred when concomitant cardiac surgery needed
- Alcohol septal ablation — alternative for non-surgical candidates
SCD prevention: [2][6]
- ICD for secondary prevention (prior cardiac arrest/sustained VT)
- ICD for primary prevention based on individual risk marker assessment (≥1 major risk factor)
- Reassess SCD risk every 1–2 years
Atrial fibrillation management: [1][7]
- Anticoagulation is strongly recommended for all HCM patients with AF regardless of CHA₂DS₂-VASc score
- Rhythm control preferred for symptomatic AF
17. Disposition
Admit for
- Acute hemodynamic instability / hypotension
- Syncope with suspected arrhythmic etiology
- New sustained ventricular arrhythmia or cardiac arrest
- Acute decompensated heart failure (NYHA III–IV)
- New-onset rapid atrial fibrillation with hemodynamic compromise
- Post-septal reduction therapy
Observation for
- Presyncope with borderline hemodynamics
- New AF with controlled rate but uncertain stability
Discharge with close follow-up if
- Stable, known HOCM with mild symptom exacerbation attributable to identifiable trigger (dehydration, medication non-adherence)
- No syncope, no hemodynamic instability, no new arrhythmia
- Adequate oral intake and stable vital signs
Specialist consultation triggers: All patients with HCM should be managed in conjunction with a comprehensive HCM center — these centers have better outcomes. [4][12] Urgent cardiology consultation for new diagnosis, syncope, arrhythmia, or refractory symptoms.
18. Follow-Up / Return Precautions
Routine follow-up: [4][12]
- Cardiology re-evaluation every 12 months (or up to 24 months if stable)
- Annual: echocardiogram + 12-lead ECG
- Every 1–3 years: ambulatory ECG monitoring (Holter or wireless patch)
- Every 3–5 years: contrast CMR (or sooner if clinical concern)
- SCD risk reassessment every 1–2 years [6]
- First-degree family member screening: ECG + echocardiography every 1–3 years (pediatric relatives) or 3–5 years (adult relatives) [4]
Return precautions — instruct patients to seek immediate care for:
- Syncope or near-syncope
- Sustained palpitations or irregular heartbeat
- Worsening dyspnea at rest or with minimal exertion
- Chest pain not relieved by rest
- ICD shocks
Patient counseling
- Maintain adequate hydration at all times; avoid dehydration [8][11]
- Avoid sudden intense exertion; individualized exercise guidance per shared decision-making with cardiologist [7]
- Avoid vasodilators, stimulants, and excessive alcohol/caffeine [8]
- Educate on medication adherence and side effects
- Reassure that most patients with HCM achieve normal longevity with appropriate management [12]
References
1. Cardiomyopathy: A Guide for Primary Care. — Coppiano J, Carrasco M, Asif I. American Family Physician. 2026.
2. Hypertrophic Cardiomyopathy. — Braunwald E. The New England Journal of Medicine. 2025.
3. Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy. — Dybro AM, Rasmussen TB, Nielsen RR, et al. Journal of the American College of Cardiology. 2021.
4. Diagnosis and Management of Hypertrophic Cardiomyopathy: Updated Guidelines From the ACC/AHA. — Leggit JC, Whitaker D. American Family Physician. 2022.
5. Hypertrophic Obstructive Cardiomyopathy. — Veselka J, Anavekar NS, Charron P. Lancet. 2017.
6. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. — Ommen SR, Ho CY, Asif IM, et al. Journal of the American College of Cardiology. 2024.
7. Current Management of Hypertrophic Cardiomyopathy. — Sikand N, Stendahl J, Sen S, Lampert R, Day S. BMJ. 2025.
8. Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. — Maron BJ, Desai MY, Nishimura RA, et al. Journal of the American College of Cardiology. 2022.
9. FDA Orange Book. — FDA Orange Book. 2026.
10. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. — Garcia-Pavia P, Maron MS, Masri A, et al. The New England Journal of Medicine. 2025.
11. Comprehensive Evaluation of Hypertrophic Cardiomyopathy: European Journal of Heart Failure Expert Consensus Document. — Martens P, Olivotto I, Garcia-Pavia P, et al. European Journal of Heart Failure. 2026.
12. Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. — Maron BJ, Desai MY, Nishimura RA, et al. Journal of the American College of Cardiology. 2022.
13. Hypertrophic Cardiomyopathy: A Practical Approach to Guideline Directed Management. — Ommen SR, Semsarian C. Lancet. 2021.
14. The Adolescent Athlete and the Team Physician: A Consensus Statement. 2025 Update. — Putukian M, Leclere LE, Herring SA, et al. Medicine and Science in Sports and Exercise. 2026.
15. Advanced Imaging Insights in Apical Hypertrophic Cardiomyopathy. — Hughes RK, Knott KD, Malcolmson J, et al. JACC. Cardiovascular Imaging. 2020.
16. Inherited Heart Diseases. — Antoni Bayés De Luna, Miquel Fiol‐Sala, Antoni Bayés‐Genís, et al. Clinical Electrocardiography. 2021.